Literature DB >> 32354919

Neoadjuvant Chemotherapy for Patients With Diaphragmatic Lesions: A Prognostic Postoperative Analysis.

Motoaki Saito1, Suguru Odajima2, Masahiro Ezawa2, Yasushi Iida2, Kazu Ueda2, Nozomu Yanaihara2, Hiroshi Tanabe2, Hirokuni Takano2, Kyosuke Yamada2, Aikou Okamoto2.   

Abstract

BACKGROUND/AIM: We aimed to analyse the prognosis of patients who underwent primary debulking surgery (PDS) and those who underwent interval debulking surgery (IDS) following four courses of paclitaxel+ carboplatin as preoperative chemotherapy to examine the usefulness of preoperative chemotherapy. PATIENTS AND METHODS: We included 45 patients with epithelial ovarian and peritoneal cancers accompanied with diaphragmatic lesions who underwent standard surgery combined with diaphragmatic surgery at two related institutions in January 2010-December 2013. Using medical records, we surveyed the recurrence period, recurrence site, and date of last confirmed survival, and analysed prognosis.
RESULTS: The PDS and IDS groups comprised 32 and 13 patients (overall survival, 61.2 and 43.2 months), respectively. Progression-free survival in the PDS and IDS groups was 31.2 and 16.8 months, respectively.
CONCLUSION: NAC-IDS can be a standard treatment option for patients with a tumour in the triangular ligament, in whom complete surgery is difficult. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Neoadjuvant chemotherapy; diaphragmatic lesions; ovarian cancer; peritoneal cancer

Mesh:

Year:  2020        PMID: 32354919      PMCID: PMC7279847          DOI: 10.21873/invivo.11902

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  9 in total

1.  Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

Authors:  A P M Heintz; F Odicino; P Maisonneuve; M A Quinn; J L Benedet; W T Creasman; H Y S Ngan; S Pecorelli; U Beller
Journal:  Int J Gynaecol Obstet       Date:  2006-11       Impact factor: 3.561

2.  Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis.

Authors:  Robert E Bristow; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2006-07-27       Impact factor: 5.482

3.  Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.

Authors:  Sean Kehoe; Jane Hook; Matthew Nankivell; Gordon C Jayson; Henry Kitchener; Tito Lopes; David Luesley; Timothy Perren; Selina Bannoo; Monica Mascarenhas; Stephen Dobbs; Sharadah Essapen; Jeremy Twigg; Jonathan Herod; Glenn McCluggage; Mahesh Parmar; Ann-Marie Swart
Journal:  Lancet       Date:  2015-05-19       Impact factor: 79.321

4.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

Authors:  Ignace Vergote; Claes G Tropé; Frédéric Amant; Gunnar B Kristensen; Tom Ehlen; Nick Johnson; René H M Verheijen; Maria E L van der Burg; Angel J Lacave; Pierluigi Benedetti Panici; Gemma G Kenter; Antonio Casado; Cesar Mendiola; Corneel Coens; Leen Verleye; Gavin C E Stuart; Sergio Pecorelli; Nick S Reed
Journal:  N Engl J Med       Date:  2010-09-02       Impact factor: 91.245

5.  Success rate and safety of tumor debulking with diaphragmatic surgery for advanced epithelial ovarian cancer and peritoneal cancer.

Authors:  Motoaki Saitou; Yasushi Iida; Hiromi Komazaki; Chikage Narui; Kanae Matsuno; Ayako Kawabata; Kazu Ueda; Hiroshi Tanabe; Satoshi Takakura; Seiji Isonishi; Hiroshi Sasaki; Aikou Okamoto
Journal:  Arch Gynecol Obstet       Date:  2014-09-04       Impact factor: 2.344

6.  What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?

Authors:  D S Chi; E L Eisenhauer; J Lang; J Huh; L Haddad; N R Abu-Rustum; Y Sonoda; D A Levine; M Hensley; R R Barakat
Journal:  Gynecol Oncol       Date:  2006-05-22       Impact factor: 5.482

7.  Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study.

Authors:  Carsten Lindberg Fagö-Olsen; Bent Ottesen; Henrik Kehlet; Sofie L Antonsen; Ib J Christensen; Algirdas Markauskas; Berit J Mosgaard; Christian Ottosen; Charlotte H Soegaard; Erik Soegaard-Andersen; Claus Hoegdall
Journal:  Gynecol Oncol       Date:  2013-12-07       Impact factor: 5.482

8.  Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).

Authors:  Andreas du Bois; Alexander Reuss; Eric Pujade-Lauraine; Philipp Harter; Isabelle Ray-Coquard; Jacobus Pfisterer
Journal:  Cancer       Date:  2009-03-15       Impact factor: 6.860

9.  Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.

Authors:  Anna Fagotti; Gabriella Ferrandina; Giuseppe Vizzielli; Francesco Fanfani; Valerio Gallotta; Vito Chiantera; Barbara Costantini; Pasquale Alessandro Margariti; Salvatore Gueli Alletti; Francesco Cosentino; Lucia Tortorella; Giovanni Scambia
Journal:  Eur J Cancer       Date:  2016-03-19       Impact factor: 9.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.